DEVELOPMENT CIRCADIAN RHYTHM-BASED DRUG REPURPOSING STRATEGY FOR AD
Home institution: Teesside University – UK (24 months)
Host institution: Bologna University – Italy (10 months)
PhD Enrolment #1: Teesside University - UK
PhD Enrolment #2: Bologna University – Italy
Supervisor #1: Xinzhong Li
Supervisor #2: Elisa Uliassi
Intersectoral Secondment: Nostrum Biodiscovery – Spain
Objectives: The School of Health and Life Sciences, Teesside University, is looking to appoint one Early-Stage Researcher (ESR) within a fixed term of 36 months to participate to the Horizon Europe Marie Curie Doctoral Network project “TClock4AD”. This Research Fellow will be funded by UK Research and Innovation and carry out the following project: “Development of circadian rhythm-based drug repurposing strategy for Alzheimer’s disease”. The major objective is to develop novel strategies considering genetics issues and circadian clock dysfunction in drug repurposing for AD in silico study. State-of-the-art statistical and machine learning including deep learning strategies will be developed to integrate publicly available multi-omics data, newly generated omics data in TClock4AD network with drug relevant databases, e.g., Drugs@FDA for systematic and comprehensive drug repositioning. Cognitive status, gender, and genetic features as well as the onset of the disease will be considered -if available- from a personalized perspective, as well as circadian clock dysfunction.
The doctoral candidate will work for two years in UK (Teesside University) and for 10 months in Bologna (University of Bologna) and will be involved in a 2-month secondment to a Spanish company (Nostrum Biodiscovery).
Expected outcomes: The fellow is expected to generate breakthrough ideas in the assigned area of research, as well as to carry out research in line with the project plan. The fellow is also expected to contribute to dissemination and communication activities, besides actively collaborating within the TClock4AD network.
